Medicare Enrolled
Dr. Rene Castillo, MD
Hematology & Oncology · Austin, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Castillo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Castillo? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Castillo
Dr. Rene Castillo is a hematology & oncology in Austin, TX, with 19 years in practice. Based on federal Medicare data, Dr. Castillo performed 243,953 Medicare services across 5,905 unique beneficiaries.
Between the years covered by Open Payments, Dr. Castillo received a total of $952 from 17 pharmaceutical and/or device companies across 44 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Castillo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 1% volume in TX$ $952 industry payments
Medicare Practice Summary
Medicare Utilization ↗243,953
Medicare services
Top 1% in TX for hematology & oncology
5,905
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~12,840 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 68,850 | $0 | $5 |
| Iron sucrose injection (Venofer) | 61,300 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 16,830 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 15,300 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 11,000 | $0 | $33 |
| Nivolumab injection (Opdivo) | 10,800 | $24 | $76 |
| Paclitaxel chemotherapy injection | 10,752 | $0 | $8 |
| Anti-nausea injection (fosaprepitant) | 9,300 | $0 | $5 |
| Daratumumab injection (Darzalex) | 7,920 | $38 | $128 |
| Denosumab injection (Prolia/Xgeva) | 6,000 | $19 | $66 |
| Contrast dye for imaging (iodine-based) | 2,850 | $0 | $3 |
| Dexamethasone injection (steroid) | 2,547 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 2,370 | $6 | $28 |
| Complete blood count (CBC) with differential | 1,658 | $8 | $36 |
| Blood draw (venipuncture) | 1,641 | $8 | $20 |
| Comprehensive metabolic blood panel | 1,372 | $10 | $64 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,260 | $1 | $114 |
| Immune globulin infusion (Octagam) | 1,100 | $34 | $236 |
| Office visit, established patient, complex (40-54 min) | 844 | $132 | $496 |
| Office visit, established patient (30-39 min) | 729 | $86 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 680 | $0 | $24 |
| Ferritin level test (iron stores) | 482 | $13 | $60 |
| Iron level test | 480 | $6 | $27 |
| Iron binding capacity test | 480 | $9 | $35 |
| Administration of chemotherapy into vein, 1 hour or less | 425 | $101 | $707 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 418 | $48 | $313 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 417 | $22 | $157 |
| Injection, zoledronic acid, 1 mg | 404 | $7 | $431 |
| Injection, carboplatin, 50 mg | 368 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 332 | $2 | $13 |
| Drug injection, under skin or into muscle | 318 | $11 | $96 |
| Flow cytometry, additional marker | 312 | $19 | $180 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 312 | $272 | $2,762 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 240 | $73 | $1,348 |
| Injection, potassium chloride, per 2 meq | 220 | $0 | $1 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 216 | $20 | $128 |
| Infusion, normal saline solution , 1000 cc | 201 | $2 | $19 |
| Lactate dehydrogenase (enzyme) level | 194 | $6 | $31 |
| Microscopic examination for white blood cells with manual cell count | 184 | $4 | $22 |
| Complete blood count (CBC), automated | 184 | $6 | $34 |
| Injection of additional new drug or substance into vein | 180 | $12 | $108 |
| Administration of additional new drug or substance into vein, 1 hour or less | 174 | $49 | $344 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 169 | $57 | $211 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 158 | $134 | $3,675 |
| Injection, diphenhydramine hcl, up to 50 mg | 130 | $1 | $7 |
| Carcinoembryonic antigen (cea) protein level | 117 | $19 | $99 |
| Reticulated (young) platelet measurement | 106 | $35 | $143 |
| Infusion into a vein for hydration, each additional hour | 104 | $9 | $75 |
| Administration of chemotherapy into vein, each additional hour | 102 | $22 | $161 |
| Infusion into a vein for hydration, 31-60 minutes | 100 | $25 | $256 |
| Unclassified drugs | 91 | $1 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 86 | $26 | $145 |
| New patient office visit (45-59 min) | 83 | $117 | $565 |
| Magnesium level test | 81 | $7 | $29 |
| Hospital follow-up visit, high complexity | 72 | $93 | $357 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 71 | $177 | $700 |
| Immunoglobulin level test | 66 | $9 | $56 |
| PSA test (prostate cancer screening) | 65 | $18 | $94 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 63 | $16 | $100 |
| Injection of drug or substance into vein | 60 | $25 | $247 |
| New patient office visit, complex (60-74 min) | 56 | $167 | $709 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 54 | $178 | $700 |
| Vitamin B-12 level test | 52 | $15 | $76 |
| Measurement of immunoglobulin light chains | 52 | $17 | $60 |
| Folic acid level test | 38 | $14 | $73 |
| Drawing of blood for a medical problem | 37 | $70 | $264 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 37 | $127 | $500 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 37 | $328 | $1,722 |
| Administration of additional new drug or substance into vein using push technique | 35 | $44 | $289 |
| Irrigation of implanted venous access drug delivery device | 33 | $16 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 24 | $16 | $94 |
| CT scan of abdomen and pelvis with contrast | 23 | $171 | $1,067 |
| Ct scan of chest with contrast | 21 | $53 | $821 |
| Application of on-body injector for under skin injection | 20 | $14 | $96 |
| Red blood count, automated test | 15 | $4 | $23 |
| Protein measurement, serum | 13 | $11 | $99 |
| Immunologic analysis technique on serum | 13 | $29 | $108 |
| Flow cytometry technique for dna or cell analysis, first marker | 13 | $52 | $298 |
| Initial hospital admission, high complexity | 12 | $136 | $694 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.2% high complexity
66.5% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$952
Total received (2018-2024)
Avg $159/year across 6 years
Bottom 29% in TX for hematology & oncology
17
Companies
44
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$618 (64.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$334 (35.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$148
2023$239
2022$216
2021$26
2019$168
2018$155
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$241
Stryker Corporation
$170
Sunovion Pharmaceuticals Inc.
$122
Janssen Pharmaceuticals, Inc
$76
PFIZER INC.
$62
E.R. Squibb & Sons, L.L.C.
$45
Novartis Pharmaceuticals Corporation
$44
AstraZeneca Pharmaceuticals LP
$35
JAZZ PHARMACEUTICALS INC.
$30
Seagen Inc.
$24
Boston Scientific Corporation
$20
Regeneron Healthcare Solutions, Inc.
$17
Genentech USA, Inc.
$16
Puma Biotechnology, Inc.
$15
Celgene Corporation
$12
Gilead Sciences, Inc.
$12
Exelixis Inc.
$12
Top 3 companies account for 55.9% of total payments
Associated products mentioned in payments ›
CALQUENCE · Cabometyx · DARZALEX · ELIQUIS · ERLEADA · Fabhalta · IBRANCE · IMBRUVICA · INLYTA · LIBTAYO · LONHALA MAGNAIR · MAKO · OPDIVO · OXBRYTA · PROMACTA · Perjeta · Pomalyst · TUKYSA · TheraSphere Y90 Glass Microspheres 10 GBq · Utibron · XARELTO · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (65%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
26
Per 100K population
2.0
County median income
$97,169
Nearest hospital
AUSTIN OAKS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Castillo is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Castillo experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Castillo performed 68,850 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Castillo receive payments from pharmaceutical companies?
Yes. Dr. Castillo received a total of $952 from 17 companies across 44 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Castillo's costs compare to other hematology & oncologys in Austin?
Dr. Castillo's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Castillo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Austin
Browse hematology & oncologys in Austin ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Stryker Corporation Payments to Doctors
See all physicians who received payments from Stryker Corporation.
By company
Sunovion Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Sunovion Pharmaceuticals Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology